BioSpace News Archive

Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced the first patients have been dosed in its global Phase 1 clinical trial of ADG126 for the treatment of various advanced solid tumors.

Ipsen Biopharmaceuticals Canada Inc. today announced the commercial availability of INCRELEX® (mecasermin) for the treatment of growth failure in children and adolescents from 2 to 18 years with confirmed severe primary insulin-like growth factor-1 deficiency (SPIGFD), following its Health Canada approval in December 2020.

Lyell Immunopharma, Inc., an immuno-oncology company dedicated to the mastery of T cells to cure solid tumors, announced the appointment of Richard Sherry, M.D., as Senior Vice President, TIL Specialist and Clinical Lead.

Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced publication of the pivotal manuscript from the AMPREVENCE clinical trial in the highly respected American Journal of Obstetrics and Gynecology (AJOG). This double-blinded, placebo-controlled, multicenter study of EVO100 met its primary and secondary efficacy endpoints

will augment the company’s thermal packaging solutions with Cloudleaf’s Digital Visibility Platform to prevent spoilage and improve delivery efforts for critical drugs and biologics, including the vaccines deployed to battle the COVID-19 pandemic

Patients and caregivers reported a greater ability to complete activities of daily livingwith increased independence

Perception Neuroscience, an atai Life Sciences company focused on developing innovative therapies in neuropsychiatric disorders, and Otsuka Pharmaceutical Co., Ltd., announce a collaboration and licensing agreement for the development and commercialization of Perception’s lead molecule, PCN-101 in Japan as a potential treatment for mood disorders such as major depressive disorder and treatment-resistant depression.